首页> 美国卫生研究院文献>The Cochrane Database of Systematic Reviews >Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR

【2h】

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR

机译：表皮生长因子受体（EGFR）酪氨酸激酶抑制剂与单药化疗相比作为非小细胞肺癌野生型或EGFR未知状态的二线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:The aim of this systematic review is to evaluate the effectiveness and safety of EGFR‐TKIs versus single‐agent chemotherapy as second‐line treatments in patients with advanced NSCLC and wild‐type or unknown status for EGFR.

机译：这是Cochrane评估（干预）的方案。目的如下：本系统综述旨在评估EGFR-TKIs与单药化疗作为晚期NSCLC和EGFR野生型或未知状态患者的二线治疗的有效性和安全性。

著录项

期刊名称 The Cochrane Database of Systematic Reviews
作者
Perrine Créquit; Amelie Yavchitz; Ludovic Trinquart; Philippe Ravaud; Jacques Cadranel;
展开▼
作者单位

展开▼
年(卷),期 -1(2018),1
年度 -1
页码 CD012901
总页数 12
原文格式 PDF
正文语种
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
2. FIRST-LINE TREATMENT WITH CYTOTOXIC CHEMOTHERAPY VERSUS EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) IN PATIENTS WITH EGFR WILD-TYPE ADVANCED LUNG ADENOCARCINOMA [J] . Chai Chee Shee, Liam Chong-Kin Respirology : . 2015,第Suppla3期

机译：EGFR野生型晚期肺腺癌患者的细胞毒性化学疗法与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的一线治疗
3. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
4. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, The oncologist . 2015,第3期

机译：吸烟状态对非小细胞肺癌患者无进展生存的作用
5. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
6. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
7. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [O] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, 2015

机译：吸烟状态在非小细胞肺癌患者无进展生存中的作用该患者具有接受一线EGFR酪氨酸激酶抑制剂对铂类双重化疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的Meta分析。
8. >Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Wen Gao, Jing He, Shi-Dai Jin, 2019

机译：>初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制剂的抗血液抗性抗血液肺癌患者T790M突变抗性抗性后，抗抗血疱剂患者的抗性，抗抗血管生长因子受体酪氨酸激酶抑制剂

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR

摘要

著录项

相似文献

相关主题

期刊订阅